Candid Therapeutics
Clinical trials sponsored by Candid Therapeutics, explained in plain language.
-
New drug aims to tame severe allergies by lowering key antibody
Disease control TerminatedThis early-stage study tests a new drug called cizutamig in about 20 adults with IgE-mediated allergies, including food allergies. The main goal is to see if the drug can safely lower IgE levels, which are antibodies that trigger allergic reactions. Researchers will also monitor …
Phase: PHASE1 • Sponsor: Candid Therapeutics • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug CND261 tested for rheumatoid arthritis relief
Disease control OngoingThis early-stage study tests a new drug, CND261, in 47 adults with moderate to severe rheumatoid arthritis who haven't responded well to other treatments. The main goal is to check the drug's safety and how the body processes it. Researchers will also look for signs that it might…
Phase: PHASE1 • Sponsor: Candid Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC